Winston Kirton Says Greater Clinical Trial Diversity Is Good Business, Should Be Incentivized

News / November 25, 2022

On Nov. 25, 2022, Pink Sheet published an article titled “Clinical Trial Diversity Would Benefit from Regulatory, Financial Incentives, Experts Say,” and the piece referenced remarks Partner Winston Kirton gave at a recent Food and Drug Law Institute conference.

Kirton told conference attendees that improving trial diversity from the beginning of drug development through commercialization is not simply a social issue. “It will provide better data to regulators,” he said. Furthermore, while it would be nice if greater diversity happened on its own, “We live in a society and in a country where incentives matter.”

Read the article (subscription required).

Related Services